Brought to you by 
Grail plans Series B round in excess of $1bn; closes initial tranches
21 Nov 2017
Executive Summary
Molecular diagnostics firm Grail Inc. (founded by Illumina last year) announced plans to raise at least $1bn through a Series B round from undisclosed private and strategic investors. The round is expected to close by the end of the first quarter. Proceeds will support development of the company's first blood-based cancer diagnostics, and will also be used to repurchase a portion of Illumina's stake. Following the transaction, Illumina will only own less than 20%, and instead of being a division, Grail will become one of Illumina's largest sequencing customers.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Grail plans Series B round in excess of $1bn; closes initial tranches
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice